Abbott’s new coated Niaspan® (niacin extended-release tablets) has recently been approved by the USFDA.
Niaspan® - the leading medication in boosting HDL (good) cholesterol - is the only USFDA-approved, once-daily extended-release prescription niacin formulation for the treatment of lipid disorders with can significantly raise HDL cholesterol.
Niacin - Niaspan®’s active ingredient - is also indicated for the secondary prevention of heart attacks, to promote regression of coronary atherosclerosis in patients with history of coronary artery disease (in combination with a bile acid binding resin).
According to Eugene Sun, M.D., vice president of Global Pharmaceutical Clinical Development, Abbott (NYSE: ABT):
"Niaspan has the proven ability to elevate good cholesterol, a known risk factor in cardiovascular disease. With the FDA approval of a new Niaspan coated tablet, our next step is to expand upon two published studies to determine the effect on flushing intensity. We'll do that by initiating larger clinical studies."
Niaspan® has been available since 1997.
Read the full press release.
[Photo Credit: kospharm]
» Abbott Laboratories Inc. from PharmaGazette
Abbott Laboratories' (NYSE:ABT) finds itself at #14 for research and development budget with $1.71 bn EUR and #9 for sales in 2006. Abbott did issue a recall on blood pressure monitors in September and received FDA approval for Niaspan indicat... [Read More]
Tracked on: December 14, 2007 10:48 AM | Permalink to Trackback